Avila Therapeutics: Exquisite targeting, compelling chemistry

With a platform to design and develop covalent drugs that have the depth and breadth to treat viral infections, cancers and autoimmune diseases, Avila Therapeutics in just three years has attracted USD 51 million in financing, and in July announced an option agreement with Novartis valued at USD 200 million in upfront payments and milestones. Read more »

Panel: Anatomy of a USD 200 million option deal

In July, 2009, Avila and Novartis entered into an option agreement on Avila’s advancement of a novel covalent drug program that included upfront and milestones payments to Avila, as well as an equity investment.

A rare opportunity to examine the details of a landmark deal by questioning partners on both sides of the negotiating table presents itself at BIO-Europe 2009 during a panel discussion Monday, November 2 at 1:00 pm. Read more »

Read more »